Development and medical application of unsaturated carbaglycosylamine glycosidase inhibitors.
This article reviews synthesis and structures of carbaglycosylamines, a group of carbocyclic sugar analogues. Some unsaturated derivatives are known to be potent glycosidase inhibitors. Among them, N-octyl-4-epi-beta-valienamine as a lysosomal beta-galactosidase inhibitor is currently undergoing a new molecular therapeutic trial (chemical chaperone therapy) for control of the human beta-galactosidase deficiency disorder, G(M1)-gangliosidosis.
Ogawa
Seiichiro
S
Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, Hiyoshi, Yokohama, Japan. sogawa379@ybb.ne.jp
Kanto
Miki
M
Suzuki
Yoshiyuki
Y
D000818:Animals; D053138:Cyclohexenes / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D016537:Gangliosidosis, GM1 / Q000188:drug therapy; D006026:Glycoside Hydrolases / Q000037:antagonists & inhibitors*; D006595:Hexosamines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D018832:Molecular Chaperones / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D053138:Cyclohexenes; D004791:Enzyme Inhibitors; D006595:Hexosamines; D018832:Molecular Chaperones; C116532:N-octyl-beta-valienamine; C030791:valienamine; D006026:Glycoside Hydrolases